Current management of rheumatoid arthritis

Managed Care Interface

Volumn 20, Issue 7, 2007, Pages 18-24

  Tambar, Siddharth ^a   Ruderman, Eric M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; AZATHIOPRINE; BIOLOGICAL FACTOR; CERTOLIZUMAB PEGOL; CHLOROQUINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; NEW DRUG; PENICILLAMINE; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

CANCER RISK; CHRONIC INFLAMMATION; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DYSLIPIDEMIA; HEPATITIS B; HUMAN; INFECTION RISK; LIVER FUNCTION TEST; LIVER TOXICITY; LOADING DRUG DOSE; LUNG CANCER; LUPUS LIKE SYNDROME; LYMPHOMA; MONOTHERAPY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS REACTIVATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES;

EID: 34548014292     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Goronzy J, Weyand C: Rheumatoid arthritis: Epidemiology, pathology, and pathogenesis, in Klippel J, Crofford L, Stone J (eds): Primer on the Rheumatic Diseases. Atlanta, Arthritis Foundation, 2001.
2. Ragan C: The clinical features of rheumatoid arthritis: Prognostic indices. JAMA 1962;181:663-667.
3. Fuchs HA, Kaye JJ, Callahan LF, et al: Evidence of significant radiographic damage in rheumatoid arthritis within the first two years of disease. J Rheumatol 1989;16:585-591.
4. van der Heide A, Remme CA, Hofman DM, et al: Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995;38:1466-1474.
5. McQueen FM, Stewart N, Crabbe J, et al: Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998;57:350-356.
6. van der Heijde DM, van Leeuwen MA, van Riel PL, et al: Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995;22: 1792-1796.
7. Weinblatt ME, Coblyn JS, Fox DA, et al: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312: 818-822.
8. Williams HJ, Willkens RF, Samuelson Jr CO, et al: Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: A controlled clinical trial. Arthritis Rheum 1985;28:721-730.
9. Erkan D, et al: Rheumatologists' optimal choice of first-line rheumatoid arthritis (RA) therapy in 2002. Presented at the European League Against Rheumatism. Lisbon, Portugal, June 18-21, 2003.
10. Gubner R, August S, Ginsberg V: Therapeutic suppression of tissue reactivity II: Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951;221:176-182.
11. Hoffmeister RT: Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983;75:69-73.
12. Weinblatt ME, Kaplan H, Germain BF, et al: Methotrexate in rheumatoid arthritis: A five-year prospective multicenter study. Arthritis Rheum 1994;37:1492-1498.
13. Willkens RF, Watson MA: Methotrexate: A perspective of its use in the treatment of rheumatic diseases. J Lab Clin Med 1982;100:314-321.
14. Rau R, Wassenberg S: Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. J Rheumatol 1999;26:2280-2281.
15. Weinblatt ME, Weissman BN, Holdsworth DE, et al: Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-month update. Arthritis Rheum 1992;35:129-137.
16. Choi HK, Hernan MA, Seeger JD, et al: Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 2002;359:1173-1177.
17. Pincus T, O'Dell JR, Kremer JM: Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventive strategy. Ann Intern Med 1999;131:768-774.
18. Kremer JM, Genovese MC, Cannon GW, et al: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-733.
19. Weinblatt ME, Keystone EC, Furst DE, et al: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
20. Breedveld FC, Weisman MH, Kavanaugh AF, et al: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
21. Genovese MC, Bathon JM, Martin RW, et al: Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46: 1443-1450.
22. Bathon JM, Martin RW, Fleischmann RM, et al: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593.
23. Smolen JS, van der Heijde DM, St Clair EW, et al: Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. Arthritis Rheum 2006;54: 702-710.
24. Landewe R, van der Heijde D, Klareskog L, et al: Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119-3125.
25. Klareskog L, van der Heijde D, de Jager JP, et al: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004;363:675-681.
26. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al: Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-1074.
27. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2005;52: 3381-3390.
28. Moreland LW, Schiff MH, Baumgartner SW, et al: Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 1999;130:478-486.
29. Elliott MJ, Maini RN, Feldmann M, et al: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-1110.
30. Furst DE, Gaylis N, Bray V, et al: Open label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: The OPPOSITE study. Ann Rheum Dis 2007 (epub ahead of print).
31. Haraoui B, Keystone EC, Thorne JC, et al: Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004;31:2356-2359.
32. Maini RN, Breedveld FC, Kalden JR, et al: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41: 1552-1563.
33. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al: Comparison of treatment strategies in early rheumatoid arthritis: A randomized trial. Ann Intern Med 2007;146:406-415.
34. Grigor C, Capell H, Stirling A, et al: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004;364:263-269.
35. Quinn MA, Conaghan PG, O'Connor PJ, et al: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52: 27-35.
36. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, et al: Attenuated response to purified protein derivative in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:1360-1361.
37. Nizam S, Emery P: Attenuated response to purified protein derivative in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:980.
38. Efthimiou P, Sood S: QuantiFERON TB Gold Test: The new standard for screening of latent tuberculosis in patients with rheumatoid arthritis? Ann Rheum Dis 2007;66:276.
39. Bongartz T, Sutton AJ, Sweeting MJ, et al: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295: 2275-2285.
40. Chung ES, Packer M, Lo KH, et al: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107: 3133-3140.
41. Cohen SB, Emery P, Greenwald MW, et al: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806.
42. Emery P Fleischmann R, Filipowicz-Sosnowska A, et al: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase 11B randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-1400.
43. Rituximab alert. Food and Drug Administration (www.fda.gov/cder/drug/ infosheets/hcp/rituximab.pdf), 2006.
44. Kremer JM, Genant HK, Moreland LW, et al: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 2006;144:865-876.
45. Genovese MC, Becker JC, Schiff M, et al: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-1123.
46. Weinblatt M, Combe B, Covucci A, et al: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807-2816.
47. Choy E, Hazleman B, Smith M, et al: Efficacy of a novel PEGy-lated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double blinded, randomized, dose escalating trial. Rheumatology 2002;41:1133-1137.
48. Zhou H, Jang H, Fleischmann RM, et al: Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007;47:383-396.
49. Dasgupta B, Corkill M, Kirkham B, et al: Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 1992;19:22-25.
50. Miltenburg AM, van Laar JM, de Kuiper R, et al: Interleukin-6 activity in paired samples of synovial fluid: Correlation of synovial fluid interleukin-6 levels with clinical and laboratory parameters of inflammation. Br J Rheumatol 1991;30:186-189.
51. Choy EH, Isenberg DA, Garrood T, et al: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46:3143-3150.
52. Maini RN, Taylor PC, Szechinski J, et al: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-2829.
53. Woo P, Wilkinson N, Prieur AM, et al: Open label phase II trial of single, ascending doses ot MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: Proof of principle of the efficacy of 1L-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005;7:1281-1288.